Using Platelet-rich Fibrin in Regenerative Endodontic Treatment in Mature Permanent Teeth

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 years and older
• All sexes
• Healthy volunteers accepted
• Adult, Older adult

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Conditions

Chronic Apical Periodontitis, Necrosis of Pulp, Acute Apical Periodontitis of Pulpal Origin, Periapical Abscess

Being tested

Using advanced platelet-rich fibrin (A-PRF+) or injectable platelet-rich fibrin (i-PRF) in regenerative endodontic treatment in mature permanent teeth.

Keywords

PRF, regenerative endodontic treatment, mature permanent treatment

Medical subject headings

Dental Pulp Necrosis, Periapical Abscess

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Using advanced platelet-rich fibrin (A-PRF+) or injectable platelet-rich fibrin (i-PRF) in regenerative endodontic treatment in mature permanent teeth.Procedure or surgery

  Also called PRF in regenerative endodontic treatment

  After obtaining informed consent, the study will be conducted over 2 appointments, 2-4 weeks apart.

  The first appointment will focus on infection control and inflammation reduction. The canal will be instrumented with a single-file system. The canal will be then irrigated sequentially with 3% sodium hypochlorite (NaOCl), saline, and 17% ethylenediaminetetraacetic Acid (EDTA) to ensure thorough disinfection. Finally, a temporary filling of Glass Ionomer Cement will be placed over an intracanal dressing of calcium hydroxide.

  At the second appointment, the final treatment will be performed based on the patient's group:

  Control Group - Blood clot method for regenerative endodontics. Experimental Group 1 - Regenerative endodontics using advanced platelet-rich fibrin (A-PRF+).

  Experimental Group 2 - Regenerative endodontics using injectable platelet-rich fibrin (i-PRF).

  All three groups will be then sealed with mineral trioxide aggregate (MTA) and a final composite resin filling.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. Clinical assessment

   • Clinical success: Absence of all the following symptoms (swelling, sinus tract, pain on percussion/bite, tooth mobility, and positive pulp sensibility).
   • Clinical failure: Presence of any one of the above symptoms.

   Measured: 1 month, 3 months, 6 months, 9 months, 12 months.

2. Radiographic assessment

   • Radiographic success: Absence or reduction of periapical pathology, measured by change in lesion size on periapical radiographs/CBCT.
   • Radiographic failure: Persistence or progression of periapical pathology, measured by change in lesion size on periapical radiographs/CBCT.

   Measured: 1 month, 3 months, 6 months, 9 months, 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted25 Sep 2025
2. Study start15 Sep 2025 (estimated)
3. Primary completion31 Aug 2027 (estimated)
4. Study completion31 Aug 2027 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for Chronic Apical PeriodontitisStudies of the same condition, open and under way.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.